An interventional study of Ixeris of sonchifolia Hance and Panax notoginseng saponins in Ischemic Stroke, sponsored by Yunling Zhang. Completed at 3 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-05.
Sponsored by Yunling Zhang · Not applicable, Interventional, and Treatment
The purpose of this study is to investigate the efficacy of fractions-based herbal combinations of clearing heat and promoting blood circulation treating acute ischemic stroke and the potential mechanism of it.
The interaction between fire-heat and blood stasis is a significant mechanism underlying pathogenesis and progress in acute ischemic stroke according to TCM theory.Clinical therapeutic effects are achieved with wide application of Ixeris of sonchifolia Hance components (KDZ injection) representing method of clearing heat and Panax notoginseng saponins components (Xueshuantong injection) representing method of promoting blood circulation.
2,593 studies on the registry are indexed under Ischemic Stroke; 931 are open to participants now.
This study's enrollment of 120 is close to the median of 120 across 1,752 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Yunling Zhang is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Comply to the Chinese guidelines of acute ischemic stroke in 2010
Treat with KDZ injection on the basis of the basic treatment
Drug: Ixeris of sonchifolia Hance
Treat with Xueshuantong injection on the basis of the basic treatment
Drug: Panax notoginseng saponins
Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
Drug: Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Also known as: KDZ injection
Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Also known as: Xueshuantong injection
KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yunling Zhang